Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart plus gemcitabine/cisplatin and lurasidone in advanced biliary tract tumors
ChiCTR2600119382Phase 2Not yet recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 1 more, sponsored by Wuxi People's Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600119382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119382.